Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
NCI – equity (deficit) – beginning of period	$ 17,752
Net loss attributable to NCI	(2,761)	$ (679)
NCI – equity (deficit) – end of period	18,802		$ 17,752
Noncontrolling Interest [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
NCI – equity (deficit) – beginning of period	17,752	$ (2,369)	(2,369)
Investment in Veris Health Inc.			6
Net loss attributable to NCI	(2,761)		(5,779)
Impact of subsidiary equity transactions	87		16,760
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise	187
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan	3,537		9,134
NCI – equity (deficit) – end of period	$ 18,802		$ 17,752